Optimizing Functional Recovery After Breast Cancer Treatment (NCT07489053)
Optimization of a Multicomponent Intervention to Foster Functional Recovery After Breast Cancer Treatment
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to determine the best way to promote participation in vocational, social, physical, and instrumental activities of daily living in people who have completed treatment for early stage breast cancer. The main question it aims to answer is: Which of the intervention components, alone or in combination, most effectively promote participation in vocational, social, physical, and instrumental activities of daily living? Participants will be asked to try one of 8 combination of three intervention components that have been shown to promote activity participation: (1) priority elicitation, (2) education, and (3) guided application involving goal setting, problem-solving and action planning.
Who can join: Review the eligibility criteria below.
Location: MGH Institute of Health Professions — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
- Individually tailored education and guided application to promote activity participation (BEHAVIORAL)
- Individually tailored guided application (BEHAVIORAL)
- Individually tailored education (BEHAVIORAL)
- Priority elicitation (BEHAVIORAL)
- Static education and guided application (BEHAVIORAL)
- Static guided application (BEHAVIORAL)
- Static education (BEHAVIORAL)
- Information (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- MGH Institute of Health Professions — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 643-5372
Email: KLyons2@mghihp.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.